{"id":47655,"date":"2017-09-29T13:31:16","date_gmt":"2017-09-29T17:31:16","guid":{"rendered":"https:\/\/asweetlife.org\/?p=47655"},"modified":"2019-04-11T04:13:26","modified_gmt":"2019-04-11T08:13:26","slug":"fda-approves-fiasp-novo-nordisks-new-fast-acting-insulin","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=47655","title":{"rendered":"FDA Approves Fiasp, Novo Nordisk’s New Fast-Acting Insulin"},"content":{"rendered":"

Today, the U.S. FDA approved Novo Nordisk\u2019s Fiasp<\/a>\u00a0(insulin aspart injection) 100 Units\/mL, a fast-acting mealtime insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes.\u00a0Fiasp\u00a0can be dosed at the beginning of a meal or within 20 minutes after starting a meal. Fiasp\u00a0is a new formulation of NovoLog, in which the addition of niacinamide (vitamin B3) helps to increase the speed of the initial insulin absorption, resulting in an onset of appearance in the blood in approximately 2.5 minutes.\u00a0Fiasp\u00a0will be available in a pre-filled delivery device FlexTouch\u00a0pen and a 10 mL vial.<\/p>\n

“With Fiasp, we’ve built on the insulin aspart molecule to create a new treatment option to help patients meet their post-meal blood sugar target,” said\u00a0Bruce Bode, MD FACE, President of Atlanta Diabetes Associates and Associate Professor at\u00a0Emory University School of Medicine. “The intention of rapid acting insulin therapy is to mimic, as much as possible, the natural physiological insulin response that occurs after meals, a process that is important for optimal A1C management.”<\/p>\n

The approval of Fiasp\u00a0is based on results from the onset phase 3a clinical development program. The clinical trials enrolled more than 2,000 adults with type 1 and type 2 diabetes to evaluate the efficacy and safety of Fiasp\u00a0administered both at mealtime and after starting a meal. Data from the trials showed that Fiasp\u00a0demonstrated a reduction in A1C in adults with type 1 and type 2 diabetes.\u00a0Common adverse reactions, excluding hypoglycemia, occuring in ?5% of subjects\u00a0included nasopharyngitis, upper respiratory tract infection, nausea, diarrhea and back pain.<\/p>\n

Fiasp\u00a0will launch at the same list price as NovoLog\u00a0and will be offered with a Savings Card program for eligible patients with commercial insurance to reduce co-pays. Fiasp\u00a0will also be available to eligible patients through the Novo Nordisk Patient Assistance Program. Patients and caregivers can obtain more information and access to the Novo Nordisk Patient Assistance Program by calling toll free at\u00a0866-310-7549.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"

…<\/p>\n","protected":false},"author":2,"featured_media":47110,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"image","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1441],"tags":[],"yoast_head":"\nFDA Approves Fiasp, Novo Nordisk's New Fast-Acting Insulin<\/title>\n<meta name=\"description\" content=\"The U.S. FDA approved Novo Nordisk\u2019s Fiasp , a fast-acting mealtime insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=47655\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Michael Aviad\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=47655\",\"url\":\"https:\/\/asweetlife.org\/?p=47655\",\"name\":\"FDA Approves Fiasp, Novo Nordisk's New Fast-Acting Insulin\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=47655#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=47655#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2017\/05\/new-fast-acting-insulin-fiasp-against-krispy-kreme.jpg\",\"datePublished\":\"2017-09-29T17:31:16+00:00\",\"dateModified\":\"2019-04-11T08:13:26+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/9f5612f866b93b894ab1ede7211e94c4\"},\"description\":\"The U.S. FDA approved Novo Nordisk\u2019s Fiasp , a fast-acting mealtime insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes.\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=47655#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=47655\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=47655#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2017\/05\/new-fast-acting-insulin-fiasp-against-krispy-kreme.jpg\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2017\/05\/new-fast-acting-insulin-fiasp-against-krispy-kreme.jpg\",\"width\":1771,\"height\":1256,\"caption\":\"New Fast-Acting Insulin Fiasp Against Krispy Kreme\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=47655#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Approves Fiasp, Novo Nordisk’s New Fast-Acting Insulin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/9f5612f866b93b894ab1ede7211e94c4\",\"name\":\"Michael Aviad\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3ba3fc6587a14adc91df0f8eec748ed5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3ba3fc6587a14adc91df0f8eec748ed5?s=96&d=mm&r=g\",\"caption\":\"Michael Aviad\"},\"description\":\"Michael Aviad is co-founder of ASweetLife. He was diagnosed with type 1 diabetes in 2002. Michael was born in Santa Barbara and grew up in Jerusalem. He studied law and after passing his bar exam went on to get an MBA with a major in finance. Michael worked for many years as an economist. He and his wife Jess, also a type 1 diabetic, have three sons. Michael loves to run and is always training for the next marathon.\",\"sameAs\":[\"https:\/\/asweetlife.org\/\"],\"url\":\"https:\/\/asweetlife.org\/?author=2\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Approves Fiasp, Novo Nordisk's New Fast-Acting Insulin","description":"The U.S. FDA approved Novo Nordisk\u2019s Fiasp , a fast-acting mealtime insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=47655","twitter_misc":{"Written by":"Michael Aviad","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=47655","url":"https:\/\/asweetlife.org\/?p=47655","name":"FDA Approves Fiasp, Novo Nordisk's New Fast-Acting Insulin","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=47655#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=47655#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2017\/05\/new-fast-acting-insulin-fiasp-against-krispy-kreme.jpg","datePublished":"2017-09-29T17:31:16+00:00","dateModified":"2019-04-11T08:13:26+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/9f5612f866b93b894ab1ede7211e94c4"},"description":"The U.S. FDA approved Novo Nordisk\u2019s Fiasp , a fast-acting mealtime insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes.","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=47655#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=47655"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=47655#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2017\/05\/new-fast-acting-insulin-fiasp-against-krispy-kreme.jpg","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2017\/05\/new-fast-acting-insulin-fiasp-against-krispy-kreme.jpg","width":1771,"height":1256,"caption":"New Fast-Acting Insulin Fiasp Against Krispy Kreme"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=47655#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"FDA Approves Fiasp, Novo Nordisk’s New Fast-Acting Insulin"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/9f5612f866b93b894ab1ede7211e94c4","name":"Michael Aviad","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3ba3fc6587a14adc91df0f8eec748ed5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3ba3fc6587a14adc91df0f8eec748ed5?s=96&d=mm&r=g","caption":"Michael Aviad"},"description":"Michael Aviad is co-founder of ASweetLife. He was diagnosed with type 1 diabetes in 2002. Michael was born in Santa Barbara and grew up in Jerusalem. He studied law and after passing his bar exam went on to get an MBA with a major in finance. Michael worked for many years as an economist. He and his wife Jess, also a type 1 diabetic, have three sons. Michael loves to run and is always training for the next marathon.","sameAs":["https:\/\/asweetlife.org\/"],"url":"https:\/\/asweetlife.org\/?author=2"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/47655"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=47655"}],"version-history":[{"count":3,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/47655\/revisions"}],"predecessor-version":[{"id":47658,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/47655\/revisions\/47658"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/47110"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=47655"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=47655"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=47655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}